Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Given the activity of single-agent Topotecan in NSCLC, there is both scientific rationale and
a medical interest in studying this agent in combination with radiation. In addition,
Topotecan administered on a weekly basis offers advantages over the daily x 5 regimen, i.e.,
the convenience of administration and fewer visits to the clinic.